|
Quintain NS and BioConsult Pty Ltd Sign Commercialisation Agreement |
|
|
Quintain NanoSystems and BioConsult Pty Ltd (BioConsult) have entered into a commercialisation agreement, focused on the strategic development of Quintain NS' NanoArray Biochip technology for bovine mastitis diagnosis.
The agreement marks the beginning of an important phase in the commercial development of the NanoArray Diagnostic Biochip platform. The expertise provided by Dr Elane Zelcer of BioConsult will enable key commercial opportunities to be identified for the diagnostic test- a highly sensitive and cost-effective method of identifying specific bacteria responsible for bovine mastitis. For more information on the NanoArray Biochip technology, click here.
BioConsult Pty Ltd provides strategy consulting and corporate development services for life science companies, research organisations and government agencies. The signing of this agreement follows the preparation of a market feasibility report by BioConsult for this application of the NanoArray Biochip technology platform and
Quintain NS is delighted to have this opportunity to further develop its commercial relationship with BioConsult. For more information on BioConsult please click here.
|